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Abstract
Background: Cigarette smoke induced oxidative stress has been shown to reduce silent information regulator
1 (Sirt1) levels in lung tissue from smokers and patients with COPD patients. Sirt1 is known to inhibit endothelial
senescence and may play a protective role in vascular cells. Endothelial progenitor cells (EPCs) are mobilized into
circulation under various pathophysiological conditions, and are thought to play an important role in tissue repair
in chronic obstructive lung disease (COPD). Therefore, Sirt1 and EPC-associated mRNAs were measured in blood
samples from patients with COPD and from cultured CD34+ progenitor cells to examine whether these genes are
associated with COPD development.
Methods: This study included 358 patients with a smoking history of more than 10 pack-years. RNA was extracted
from blood samples and from CD34+ progenitor cells treated with cigarette smoke extract (CSE), followed by
assessment of CD31, CD34, Sirt1 mRNA, miR-34a, and miR-126-3p expression by real-time RT-PCR.
Results: The expression of CD31, CD34, Sirt1 mRNAs, and miR-126-3p decreased and that of miR-34a increased in
moderate COPD compared with that in control smokers. However, no significant differences in these genes were
observed in blood cells from patients with severe COPD compared with those in control smokers. CSE significantly
decreased Sirt1 and increased miR-34a expression in cultured progenitor cells.
Conclusion: Sirt1 expression in blood cells from patients with COPD could be a biomarker for disease stability in
patients with moderate COPD. MiR-34a may participate in apoptosis and/or senescence of EPCs in smokers.
Decreased expression of CD31, CD34, and miR-126-3p potentially represents decreased numbers of EPCs in blood
cell from patients with COPD.
Keywords: miR-34a, miR-126, p53, Sirt1
Background
Cigarette smoke-induced oxidative stress is a major risk
factor for chronic obstructive pulmonary disease (COPD).
Numerous studies have indicated the presence of endo-
thelial dysfunction in smokers and in patients with COPD
[1, 2], and have also suggested that reduced numbers and/
or dysfunction of endothelial progenitor cells (EPCs)
could contribute to the tissue angiogenesis and repair
mechanisms [3–6]. EPCs, first reported by Asahara et al.
[7], play a key role in angiogenesis and in the maintenance
of vascular integrity [8, 9] and also have the potential to
maintain lung structure in smokers [10]. EPCs are bone
marrow-derived endothelial cell precursors that can mi-
grate to sites of neovascularization, differentiate into
endothelial cells, and participate in angiogenesis and
hypothetically in the maintenance of stressed lung micro-
circulation [8]. Analysis of a combination of stem cell and
endothelial cell markers is most commonly applied to
isolate EPCs from blood cells [11]. The cluster of differen-
tiation (CD) 34, also known as the hematopoietic progeni-
tor cell antigen, is a member of a family of single-pass
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transmembrane sialomucin proteins expressed on
early hematopoietic and vasculature-associated tissues
[12]. CD34+ progenitor cells differentiate into EPCs,
which express surface markers for endothelial cells,
such as CD31, vascular endothelial growth factor re-
ceptor 2. CD31, also known as the platelet endothelial
cell adhesion molecule, is mainly expressed on endo-
thelial cells, platelets, and macrophages and is thought to
be an immature and mature vascular endothelial cell
marker [8].
Micro RNAs (miRNAs) are non-coding RNA mole-
cules that modulate gene expression by binding to their
complementary sequences on target mRNAs; they can
regulate cell proliferation, differentiation and apoptosis
[13–15]. Recently, the possible involvement of two miR-
NAs, miR-34a and miR-126, in the regulation of EPCs
has been supported by animal studies using silencing of
their target genes in hematopoietic stem cells [16, 17].
The miRNAs in blood cells may affect EPC activity and
perhaps the lung maintenance program and pathogen-
esis in COPD. MiR-34a is the most intensely investigated
miRNA that is induced by p53 and its expression is
closely related to the induction of apoptosis and cell
cycle arrest in cancer cells [18]. As an NAD-induced
deacetylase, silent information regulator 1 (Sirt1) is a
transcriptional regulator, that can suppress the expres-
sion of pro-apoptotic proteins [19], and regulates p53-
dependent apoptosis by deacetylating and destabilizing
the p53 protein. It is known that Sirt1 mediates miR-
34a-induced apoptosis by regulating p53 activity, and a
positive feedback loop has been identified, wherein p53
induces miR-34a expression, thus suppressing Sirt1 and
increasing p53 activity [20]. We have previously shown
that miR-34a is associated with p53 protein expression,
both in animal emphysema models and in human COPD
lung tissues [21–23], suggesting that miR-34a, regulated
by p53, is also involved in lung tissue remodeling via the
p53 pathway. In the context of EPCs and miRNA, Zhao
et al., reported that miR-34a impairs EPC-mediated
angiogenesis by inhibiting Sirt1 in rats [16], indicating
that oxidative stress-induced p53 and miR-34a expres-
sion could induce vascular endothelial cell senescence
and decrease EPC activity through Sirt1 inhibition. MiR-
126 has been identified as the miRNA, which is highly
expressed in endothelial cells [24, 25] and also detected
in bone marrow derived cells [17]. MiR-126 plays a crit-
ical role in the regulation and development of endothe-
lial differentiation and vascular remodeling [26]. The
precursor miRNA (pre-miR-126) produces two mature
strands, miR-126-3p and miR-126-5p [24]; administra-
tion of miR-126-3p has been shown to promote the in-
corporation of Sca-1+ progenitor cells [27], suggesting
an essential role for miR-126 in the endothelial stress
response and the release of EPCs.
Here we investigated whether expression of vascular
endothelial cell genes expression in blood cells from
smokers is associated with the development of COPD. We
first analyzed the CD31 and CD34 mRNA expression in
blood cells obtained from 358 smokers to explore the as-
sociation of airflow limitation and EPC associated gene
expression. We then measured Sirt1 mRNA, and miR-34a
and miR-126 expression to clarify this association and the
regulation of oxidative stress in blood cells, cultured
CD34+ progenitor cells, and in cultured pulmonary endo-
thelial cells. We speculated that gene expression in blood
cells could be a biomarker representing the numbers
of circulating EPCs or the dysfunction of EPCs from
smoking-induced oxidative stress, which may be a marker
of effective lung tissue maintenance status.
Methods
Patients
From October 2011 to December 2014, 358 patients
were recruited from the outpatient department of the
Division of Respiratory Medicine, Kanazawa Medical
University Hospital, Department of Respiratory Medicine,
University of Fukui Hospital, and the Division of Respira-
tory Medicine, Fukui Red Cross hospital. The inclusion
criteria for enrollment were age >40 years and at least a 10
pack-year history of tobacco exposure. The study was ap-
proved by the Research Ethics Committee of Kanazawa
Medical University, University of Fukui, and Fukui Red
Cross Hospital (Protocol: NO. 0073). All subjects gave
informed consent in writing.
Pulmonary function tests were performed to deter-
mine FVC and FEV1. Diagnosis of COPD was based on
the basis of clinical history, physical examination, and
spirometric data, following the Global Initiative for Ob-
structive Lung Disease (GOLD) classification [28]. This
study included 252 patients with COPD patients and
106 smokers without COPD. The COPD patients were
classified into 3 categories (mild; GOLD I, moderate;
GOLD II, severe; GOLD III and IV) based on spiromet-
ric data (Table 1).
CT scans were acquired using either a 64 or a 128
multidetector CT scanner (Somatom Definition FLASH
or Somatom Definition AS+; Siemens Medical Solutions,
Erlangen, Germany; Brilliance 64, Phillips, Eindhoven,
Netherlands) with a slice thickness of less than 2 mm.
We calculated the % of low attenuation area (%LAA)
using a threshold of −960 HU to assess the emphysema-
tous changes and the total lung volume using a computer
software LungVision™ version 2.1(Cybernet Systems CO.
LTD., Tokyo, Japan.).
Generation of Cigarette Smoke Extract (CSE)
CSE was prepared as reported previously [29]. Briefly,
one cigarette without filters (Marlboro; Philip Morris
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International Inc; New York City, New York) was burned,
and the smoke was passed, using a vacuum pump,
through a glass Cambridge filter (Cambridge Filter Japan,
Ltd; Tokyo, Japan) with 0.20-μm pores for removing the
particles and bacteria into a vessel containing phosphate-
buffered saline (PBS) (1 mL per one cigarette). The
CSE-PBS solution was freshly prepared for each set of
experiments.
Cell culture
Human CD34+ progenitor cells and human pulmonary
microvascular endothelial cells (HPMVECs) were pur-
chased from Lonza. Human CD34+ progenitor cells were
cultured in hematopoietic progenitor cell expansion
medium supplemented with a cytokine mix (PromoCell).
HPMVECs were cultured in endothelial cell growth
medium supplemented with 5 % FBS (Lonza). The cells
were cultured in 175-cm2 tissue culture flasks and
maintained in a cell-culture incubator (37 °C, 5 %
CO2, and 95 % air) and then used for all the experi-
ments. After incubation, the human CD34+ progenitor
cells were harvested and seeded in 96-well culture
plates with or without various concentrations of CSE
for the MTS assay. Human CD34+ progenitor cells
and HPMVECs were seeded in 24-well culture plates
with or without 0.3 % CSE for RT-PCR analysis.
HPMVECs were seeded in 6-cm culture dishes with
or without 0.3 % CSE for western blot analysis, and
cultured for 24 h.
MTS assay in CD34+ progenitor cells
MTS assay was performed using a CellTiter 96® AQue-
ous One Solution Cell Proliferation Assay kit in accord-
ance with the manufacturer’s protocol. Briefly, human
CD34+ progenitor cells were seeded in 96-well culture
plates and cultured with or without various concentra-
tions (0.1 to 3 %) of CSE. The cells were then incubated
with 20 μL of CellTiter 96® AQueous One Solution
Reagent for 15 min, and absorbance at 490 nm was
measured.
Real-time RT-PCR analysis of mRNA and miRNA
Whole blood was collected from each patient into PAX-
gene Blood RNA Tubes (PreAnalytiX) using standard
phlebotomy technique and stored at −20 °C until used
for RNA extraction. RNA from the blood was extracted
using the PAXgene Blood RNA Kit (PreAnalytiX) ac-
cording to the manufacturer’s protocol. Isolation of total
RNA and miRNA from CD34+ progenitor cells and
HPMVECs was performed using an miRNeasy Mini kit
according to the manufacture’s protocol. For qPCR, the
SuperScript VILO cDNA kit (Life Technologies) was
used for mRNA analysis, and the miScript II RT kit
(Qiagen) was used for miRNA analysis. As per the
manufacturer’s instructions, 0.5 μg RNA per sample
in 20 μL and the cDNA was diluted 1:10 prior to
PCR. PCR was performed with the cDNA using specific
oligonucleotide primers. PCR was performed in duplicate
on a LightCycler™ PCR system (Roche Diagnostics,
Table 1 Characteristics of patients
Characteristics Smoking control Mild COPD Moderate COPD Severe COPD
GOLD - Stage I Stage II Stage III, IV
Number of patients 106 69 103 80
Age (years) 70.5 ± 9.4 72.2 ± 9.3 72.5 ± 8.8 73.9 ± 8.7
Gender (Male/Female) (102/4) (65/4) (98/5) (76/4)
FVC predict (%) 97.2 ± 14.2 114.1 ± 14.9* 97.3 ± 16.1 75.7 ± 18.1*
FEV1/FVC (%) 77.3 ± 6.1 64.5 ± 5.1* 52.8 ± 9.1* 39.3 ± 10.4*
FEV1% predict 96.1 ± 13.5 96.3 ± 13.3 64.5 ± 8.8* 37.5 ± 8.1*
LAA (%) 5.5 ± 6.1 10.7 ± 10.0 14.6 ± 10.7* 22.7 ± 14.6*
Smoking (Pack years) 61.4 ± 38.5 58.1 ± 33.7 60.5 ± 30.7 63.2 ± 29.2
Current smoker (no.) 31 22 29 19
Medication (no.)
LABA - 17 49 50
LAMA - 17 46 55
ICS - 11 36 38
CRP (mg/dl) 0.24 ± 0.34 0.31 ± 0.48 0.39 ± 0.77 0.46 ± 0.92
COPD Chronic obstructive pulmonary disease, GOLD Global Initiative for Obstructive Lung Disease, FEV1 % predict Forced Expiratory Volume in 1 s % predicted,
LAA Low attenuation area; change in FEV1 as a percent of baseline FEV1, LABA Long acting beta 2 agonist, LAMA Long acting muscarinic antagonist,
ICS Inhaled corticosteroid
Values are expressed as means ± SD. * p < 0.05 vs smoking control
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Meylan, France) using the DNA binding SYBR Green
dye (Roche Diagnostics) for mRNA analysis and the
miScript SYBR Green dye (Qiagen) for miRNA analysis
and detection of PCR products. The 18 s rRNA gene was
used as the reference for mRNA, and miR-103 was used
as the reference for miRNA. The sequence of the target
primers is shown in Table 2.
Western blot analysis
Cytoplasmic and nuclear proteins from HPMVECs were
prepared using the NE-PER Nuclear and Cytoplasmic
Extraction Reagents according to the manufacturer’s
protocol, and the protein extracts were analyzed for pro-
tein content using the Bradford method. Each sample
was quantified, and 40 μg of protein (cytoplasmic
protein) or 20 μg of protein (nuclear protein) was
loaded into each lane of a 4–12 % Bis-Tris Nupage
gel with MES SDS running buffer, according to the
manufacturer’s protocol. After electrophoresis, the
proteins were transferred to a PVDF membrane, and
the membrane was probed with specific primary and
secondary antibodies (Santa Cruz Biotechnology Inc.).
The ECL system was used for detecting of the proteins.
Lamin B protein was used as the reference protein for
Sirt1, and ß-actin was used as the reference protein for
p53 protein.
Measurement of Sirt1 protein expression in blood cells
from COPD patients
Whole blood was collected from 48 patients (Table 3)
into 6 ml round-bottom tubes containing EDTA, nucle-
ated cells were separated from red blood cells using
Hetasep™ (Stemcell Technologies) according to the man-
ufacture’s protocol, then the pellets of blood cells were
stored at −80 °C until measurement of Sirt1 protein ex-
pression. The Sirt1 protein expression of the stored
blood cells was measured using a human Sirt1 ELISA kit
(Abcam). The Sirt1 protein expressions in blood cells
were referenced to the protein concentration measured
by the Bradford method.
Statistical analysis
Age, smoking index expressed as pack-years, and pul-
monary function parameters were compared using the
Mann–Whitney U test. Analysis of protein and gene ex-
pression was performed using ANOVA with Turkey’s
multiple comparisons. Correlations were analyzed by the
Pearson correlation coefficient. Comparisons of circulating
gene expression between current smokers and ex-smokers
in severe COPD were performed using the Student’s t-test.
Comparisons were considered statistically significant at
P < 0.05.
Results
Patient characteristics
Age, gender, smoking history, pulmonary function data,
%LAA and serum CRP data for patients with of COPD
and control smoker subjects are summarized in Table 1.
No significant differences were observed in smoking
history (pack-years) between the groups, however, the
proportion of current smokers among patients with
severe COPD was relatively lower when compared with
those among smoking controls. The population of pa-
tients receiving inhaled corticosteroids (ICS) was rela-
tively greater among patients with severe COPD than
those among other groups. The average age and CRP of
patients with severe COPD was slightly greater when
compared to those in smoking controls, however, there
were no significant differences between the groups. The
percent FVC was significantly increased in mild COPD
and was decreased in severe COPD compared with that
in smoking control subjects. The percent LAA was sig-
nificantly increased in patients with mild, moderate, and
severe COPD compared with that in smoking control
subjects. The %LAA was significantly higher in patients
with moderate and severe COPD compared with that in
smoking control subjects, and was negatively correlated
(R = 0.458) with the %FEV1.
Expression of circulating endothelial cell gene
expressions in smokers
The expression of the circulating EPC genes (CD31 and
CD34 mRNA) was significantly decreased in patients
with moderate COPD when compared with that in
smoking control subjects. Surprisingly the expression of
these genes was higher in patients with severe COPD,
Table 2 Primer sequences used for real-time quantitative PCR
of mRNA and miRNA
Target gene Upper-primer Lower-primer
CD31 5′-AACCCACTCCCCGAC
CTAGA-3′
5′-CCAGACACCATTCCAA
AACC-3′
CD34 5′-TAAGAAGGACAGGGG
AGAGG-3′
5′-GCCAAGACCAGCAGTA
GACA-3′
Sirt1 5′-GGGGTGTCTGTTTCAT
GTGG-3′
5′-ACATCGCTTGAGGATC
TGGA-3′
IL-6 5′-GGTACATCCTCGACGG
CATC-3′
5′-TGCCTCTTTGCTGCTTTC
AC-3′
p21 5′-GGAAGACCATGTGGA
CCTGT-3′
5′-GGCGTTTGGAGTGGTA
GAAA-3′
18 s rRNA 5′-GACTCAACACGGGAA
ACCTC-3′
5′- CGCTCCACCAACTAA
GAACG-3′
miR-34a 5′-GGCAGTGTCTTAGCTG
GTTGT-3′
miR-126-3p 5′-TCGTACCGTGAGTAAT
AATGC-3′
miR-103 5′-CAGCATTGTACAGGGC
TATGA-3′
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but no significant changes were observed compared with
the smoking controls (Fig. 1).
Expression of miR-34a in subjects with moderate
COPD was significantly increased compared to that in
control subjects, and expression of miR-126-3p and Sirt1
mRNA in subjects with moderate COPD was decreased
when compared with that in control subjects (Fig. 2a, b, c).
A strong positive correlation was observed between the
expression of Sirt1 and CD31 mRNA expression (Fig. 3a),
and a weak positive correlation was observed between
the expression of CD31 mRNA and miR-126-3p
(Fig. 3b). We also found a very weak correlation be-
tween the expression of CD31 and CD34 mRNA
(Fig. 3c). However, no significant correlation was
found between CD34 expression and that of Sirt1
mRNA, miR-34a, or miR-126-3p (Fig. 3d, e, f ). Add-
itionally, we measured the blood cell Sirt1 protein
expression in patients with moderately severe COPD
and found it decreased when compared with the ex-
pression in the control subjects (Fig. 2d).
Because of the smaller population of current smokers
among the patients with severe COPD, we further ana-
lyzed circulating gene expression in these patients be-
tween former smokers (ex-smokers) and current smokers.
Although some ex-smokers showed high expressions of
CD34 mRNA, miR-34a, and miR126-3p, we did not find
significant differences in the expression of these genes
between current smokers and ex-smokers. However, a
tendency toward increased IL-6 mRNA expression was
observed in current smokers among patients with severe
COPD (Fig. 4a). We also found a tendency toward in-
creased IL-6 expression in patients with severe COPD
compared with that in patients with moderate COPD
among ex-smokers (Fig. 4b), and a strong positive correl-
ation was observed between IL-6 and Sirt1 mRNA expres-
sion in currently smoking patients with severe COPD
Table 3 Characteristics of Patients who measured Sirt1 protein expression
Characteristics Smoking control Mild COPD Moderate COPD Severe COPD
GOLD - Stage I Stage II Stage III, IV
Number of patients 12 5 20 11
Age (years) 69.6 ± 6.4 74.2 ± 5.5 75.9 ± 7.7 74.2 ± 7.6
Gender (Male/Female) (12/0) (4/1) (19/1) (10/1)
FVC predict (%) 99.2 ± 15.6 114.1 ± 5.4 97.2 ± 11.6 81.9 ± 17.5*
FEV1/FVC (%) 77.1 ± 7.6 59.4 ± 7.6* 51.0 ± 9.4* 32.7 ± 6.7*
FEV1% predict 96.6 ± 14.3 88.2 ± 8.0 63.5 ± 7.3* 34.2 ± 9.2*
Smoking (Pack years) 48.1 ± 31.7 43.0 ± 11.8 56.3 ± 31.7 68.3 ± 32.9
Current smoker (no.) 3 0 6 0
Medication (no.)
LABA - 4 17 10
LAMA - 3 16 8
ICS - 2 6 7
Values are expressed as means ± SD. *p < 0.05 vs smoking control
Fig. 1 CD31 and CD34 gene expressions in blood samples from smokers. The bar graphs show data from RT-PCR analysis of CD31 (a) and CD34
(b) mRNA expressions in blood samples from smokers. The CD31 and CD34 mRNA expression were significantly decreased in subjects with
moderate COPD compared to that in smoking control subjects. Data are expressed as mean ± SD
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(Fig. 4c). Subsequently, to exclude the possibility that ICS
therapy in severe COPD could affect the number of EPCs,
we also analyzed the circulating blood cell gene expression
in patients with severe COPD between patients receiving
ICS and those not treated with ICS. Indeed, we found a
significant decrease in Sirt1 expression and a ten-
dency toward decreased expression of CD31 and IL-6
in patients receiving ICS (Fig. 5a). We also found sig-
nificantly increased levels of IL-6 mRNA expression
in patients with severe COPD compared to those with
moderate COPD among patients who were not treated
with ICS (Fig. 5b). A positive correlation was observed
between the IL-6 and Sirt1 mRNA expression in pa-
tients with severe COPD who were not treated with
ICS (Fig. 5c).
Effects of CSE on cultured CD34+ progenitor cells and
HPMVECs
We next investigated whether CSE mediates decreased
Sirt1 expression and increased miR-34a expression in cul-
tured CD34+ progenitor cells and HPMVECs. We found
that CSE treatment significantly suppressed CD34+ pro-
genitor cell proliferation at a concentration of 0.3 % (Fig. 6).
Therefore, we used CSE at a concentration of 0.3 % for
RT-PCR analysis of Sirt1, CD31, miR-34a, and miR-126-3p
in CD34+ progenitor cells. CSE treatment significantly
suppressed Sirt1 expression and increased the expression
of p21 and miR-34a. However, no significant changes were
observed in CD34+ progenitor cells upon exposure to
0.3 % CSE (Fig. 7). We also measured the expression of
CD31 mRNA, Sirt1 mRNA, miR-34a, and miR126-3p in
cultured HPMVECs exposed to 0.3 % CSE, and found al-
most the same gene expression patterns that in the CD34+
progenitor cells (Fig. 8a). We also confirmed the decreased
expression of Sirt1 and increased expression of p53 protein
in cultured HPMVECs exposed to CSE (Fig. 8b).
Discussion
In the present study, we hypothesized that circulating
EPC-related genes and miRNA expression could be bio-
markers of the disease state in patients with COPD. We
examined EPC-related gene expression in blood cells
from smokers, and found that the expression of circulat-
ing CD31, CD34, Sirt1 genes, and miR-126-3p was de-
creased and that of miR-34a was increased in patients
with moderate COPD when compared with non-COPD
subjects. We also found a positive correlation between
CD31 and Sirt1 mRNA expression, and confirmed the
Fig. 2 Expressions of Sirt1, miR-34a and miR-126-3p in the blood samples from smokers. The bar graphs show data from RT-PCR analysis of Sirt1
mRNA (a), miR-34a (b), miR-126-3p (c) expressions, and Sirt1 protein expression (d) in the blood samples from smokers. MiR-34a expression was
significantly increased and miR-126-3p and Sirt1 mRNA and protein expression was decreased in subjects with moderate COPD compared to that
in smoking control subjects. Data are expressed as mean ± SD
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upregulation of p21 mRNA and miR-34a, and the downreg-
ulation of Sirt1 expression by exposure to CSE in cultured
CD34+ progenitor cells. Exposure to CSE downregulated
Sirt1 expression and upregulated miR-34a and p53 expres-
sion in cultured HPMVECs.
Oxidative stress can activate numerous signaling cas-
cades that lead to lung cell apoptosis. In patients with
COPD, cigarette smoke generates large amounts of free
radicals, including superoxide (O2−), hydroxyl radical,
and hydrogen peroxide (H2O2) [30]. Exposure to cigarette
smoke also causes reduce of Sirt1 expression in lung tissue
with concomitant elevation of matrix metalloproteinase-9
[31]. Oxidative stress is known to activate the tumor
suppressor, p53, which inhibits cell cycle progression and
induces apoptosis in cells with irreparable genetic damage
[32]. Previous reports have shown that Sirt1 prevents
cellular senescence by deacetylation and suppression of
p53 [33]. In contrast, Sirt1 deficiency was reported to en-
hance oxidative stress-induced cellular damage and p53
acetylation [34]. It is possible that reduced Sirt1 expres-
sion under oxidative stress conditions can promote the
acetylation of p53 and enhance miR-34a expression,
thereby resulting in impaired angiogenesis and main-
tenance of lung structure with circulating EPC and
COPD/emphysema. Our study demonstrates decreased
expression of Sirt1 and increased expression of miR-
34a, which is regulated by p53, in blood from patients
with moderate COPD and in cultured CD34+ progeni-
tor cells, in line with previous findings showing that
oxidative stress-induced cellular damage is associated
with p53 activity and Sirt1 expression [16]. Further-
more, we confirmed decreased protein expression of
Sirt1 in blood cells from patients with moderate
COPD (Fig. 2d). Previous studies showed that Sirt1
expression in blood cells is involved in diseases asso-
ciated with systemic chronic inflammatory processes
such as coronary artery disease, type 2 diabetes [35, 36].
Moreover, Mody et al., reported that decreased Sirt1 ex-
pression in pulmonary leukocyte was associated with the
development of bronchopulmonary dysplasia [37]. Thus,
the decrease of Sirt1 expression in blood cells from
COPD patients has the potential to exaggerate inflam-
matory response. However, whether the decreased
Sirt1 expression in blood cells from COPD patients is
a result or cause of disease progression, cannot be an-
swered by this study.
In the present study, we demonstrated increased ex-
pression of p21 mRNA and miR-34a in cultured CD34+
progenitor cells exposed to CSE. Both p21 and miR-34a
are regulated by p53 protein, and are known to induce
cellular senescence and apoptosis [38, 39]. No significant
differences were observed in CD31 mRNA, CD34 mRNA,
and miR-126-3p expression after CSE exposure in cul-
tured CD34+ progenitor cells (Fig. 7). This suggests that
Fig. 3 Correlation analysis between EPC related gene expressions in the blood samples from smokers. A strong positive correlation was seen
between CD31 and Sirt1 mRNA (a), and a weak positive correlation was seen between CD31 mRNA and miR126-3p expression (b). A very weak
positive correlation was seen between CD31 and CD34 mRNA expressions (c). There were no significant correlations between the expression of
CD34 and Sirt1 mRNA (d), miR-34a (e), and miR-126-3p (f). Data are expressed as mean ± SD
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decreased expression of EPC marker in patients with
moderate COPD was due to the decreased number of
blood cells expressing these EPC related genes, resulting
from senescence and apoptosis of EPCs induced by oxida-
tive stress from cigarette smoking. We also measured the
expression of these genes in cultured HPMVECs to deter-
mine whether CSE affects lung endothelial cells, which are
important in the maintenance of lung structure and par-
ticipate in the pathogenesis of pulmonary emphysema
[40]. We observed the same pattern of gene expression in
the presence of CSE in these cells as well (Fig. 8a). Add-
itionally, we confirmed that Sirt1 protein expression was
suppressed and p53 protein expression was augmented by
CSE exposure in cultured HPMVECs (Fig. 8b). Decreased
expression of Sirt1 and increased expression of p53 in
pulmonary endothelial cells could be also associated with
the pathogenesis of COPD and emphysema, in addition to
Sirt1 and its related genes in blood cells from patients
with COPD.
Although the finding of a decreased numbers of circu-
lating EPCs in patients with COPD remains controver-
sial [4, 6, 10, 41, 42], a decrease in precursor cells might
be responsible for the clinical state of patients, including
disease severity, cardiovascular complications, and COPD
exacerbations. Previous studies that show reduced EPCs
in COPD, are related to stable patients [4, 10], and in the
study by Palange, et al., current smokers, and patients with
cardiovascular complications were excluded from the ana-
lysis [4]. Conversely, studies regarding circulating EPCs in
COPD during exacerbations showed a significant increase
in the numbers of EPCs compared to those in patients
with stable COPD [42]. Our results show a decrease in the
circulating cell CD31 mRNA, CD34 mRNA and miR-126-
3p expression in patients with moderate COPD, and
might reflect a state of relative disease stability whereas
higher numbers in patients with severe COPD may be
attributable to more severe systemic inflammation and the
frequency of exacerbations and complications such as
cardiovascular diseases. In keeping with this, we observed
slight elevation in the average concentrations of CRP in
patients with severe COPD. Persistent low-grade inflam-
mation is associated with comorbidities of COPD [43],
and lung inflammation may cause an increase in inflam-
matory cytokines in the blood, which could stimulate the
circulating blood-derived endothelial progenitor cells and
angiogenesis [44].
Fig. 4 Gene expression in blood samples from patients with moderate and severe COPD between current smokers and former smokers. a The
graphs show mean and individual data from the RT-PCR analysis of CD31, CD34, IL-6, Sirt1 mRNA, miR-34a, and miR-126-3p expressions in blood
cells between current smokers and former smokers (Ex-smokers) in subjects with severe COPD. We observed a tendency toward decreased IL-6
expression in ex-smokers compared to that in current smokers. b The graphs show mean and individual data from RT-PCR analysis of IL-6 mRNA
expression in blood cells between current smokers and ex-smokers in subjects with moderate and severe COPD. c A strong positive correlation
was seen between IL-6 and Sirt1 mRNA expression among current smokers with severe COPD. A weak positive correlation was seen between IL-6
and Sirt1 mRNA expression among ex-smokers with severe COPD. Data are expressed as mean ± SD
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Since our study cohort had fewer patients with severe
COPD that were current smokers, and a relatively large
number of patients receiving ICS, we only analyzed
circulating blood cell gene expression in patients with
severe COPD, comparing between current smokers and
ex-smokers, and between patients treated with or with-
out ICS. However, we did not find any significant differ-
ences in gene expression between current smokers and
ex-smokers among patients with severe COPD (Fig. 4a).
We thus postulate that even after cessation of smoking,
oxidative stress persists in activated macrophages and
neutrophils, which are abundant in emphysematous
lungs [45, 46]. Regarding ICS treatment, even though
suppression of lung inflammation is the goal of the treat-
ment, we observed relatively decreased Sirt1 and CD31
expression in blood cells from patients with severe
COPD (Fig. 5a). This phenomenon is possibly explained
by a decreased level of Sirt1 expression in lung tissue as
a consequence of glucocorticoid treatment. Poulsen, et
al., have previously shown that activation of the p53
pathway by glucocorticoids was associated with decreased
levels of Sirt1 mRNA and protein expression in primary
human tenocytes [47]. Reduced Sirt1 activity induced by
ICS in COPD lungs could be related to increased p53
Fig. 5 Gene expression in blood samples from patients with moderate and severe COPD between patients without ICS treatment and patients
receiving ICS. a The graphs show mean and individual data from RT-PCR analysis of CD31, CD34, IL-6, Sirt1 mRNA, miR-34a, and miR126-3p
expression between patients without ICS treatment (ICS-) and patients receiving ICS (ICS +) in subjects with severe COPD. We found a significant
decrease in Sirt1 expression, and a tendency toward decreased CD31 and IL-6 expression in blood cells from patients receiving ICS. b The graphs
show mean and individual data from RT-PCR analysis of IL-6 mRNA expression between patients without ICS treatment (ICS-) and patients receiving
ICS (ICS +) in subjects with moderate and severe COPD. c A positive correlation was seen between IL-6 and Sirt1 mRNA expression among patients
without ICS treatment (ICS -) in severe COPD subjects. No significant correlation was seen between IL-6 and Sirt1 mRNA expression among patients
receiving ICS (ICS +) in subjects with severe COPD. Data are expressed as mean ± SD
Fig. 6 Effect of CSE on cell proliferation in cultured CD34+ progenitor
cells. Cultured CD34+ progenitor cells were exposed to various
concentrations of cigarette smoke extract (CSE) for 24 h, and an MTS
assay was performed. CSE significantly suppressed cell proliferation at a
concentration of 0.3 %. Data are expressed as mean ± SD (n = 8).
*P < 0.05 versus control
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Fig. 7 Effect of CSE on gene expressions in cultured CD34+ progenitor cells. Cultured CD34+ progenitor cells were exposed to 0.3 % of CSE for
24 h, and Sirt1, CD31, p21 mRNA, miR-34a, and miR-126-3p expression was measured by RT-PCR analysis. CSE treatment significantly suppressed
Sirt1 expression and increased the expression of p21 mRNA and miR-34a. Data are expressed as mean ± SD (n = 6). *P < 0.05 versus control
Fig. 8 Effect of CSE on gene and protein expression in cultured human pulmonary microvascular endothelial cells (HPMVECs). Cultured HPMVECs
were exposed to 0.3 % CSE for 24 h, and Sirt1, CD31 mRNA, miR-34a and miR-126-3p expressions were measured by RT-PCR analysis (a). Sirt1 and
p53 protein expression was measured by western blot analysis (b). CSE treatment significantly suppressed Sirt1 mRNA and protein expression and
increased miR-34a and p53 protein expression. Data are expressed as mean ± SD (n = 6 for RT-PCR analysis, n = 4 for western blot analysis). *P < 0.05
versus control
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acetylation, and could possibly enhance p53-associated
COPD/emphysema [23]. However, we cannot exclude the
possibility that patients in need of ICS treatment have
different EPC characteristics and reactions to oxidative
stress, which affect Sirt1 and CD31expression.
Likewise, the upward shift of Sirt1 expression in patients
with severe COPD could be explained by an increase in
inflammatory cytokines, different smoking status or differ-
ences in treatment compared to other groups of COPD
patients. A number of previous studies have demonstrated
that Sirt1 is closely associated with inflammation, as
Sirt1 attenuated transcriptional activation of NF-κB
and decreased the production of inflammatory cyto-
kines [48–51]. However, several previous studies have
also indicated that Sirt1 could stimulate inflammatory
cytokines and be associated with apoptosis resistance
[52–54]. In the present study, we found a tendency
for increased IL-6 expression among former smokers
in severe COPD patients compared to those with moder-
ate COPD, and a significant increase in IL-6 expression in
patients with severe COPD compared to those with mod-
erate COPD without ICS treatment (Figs. 4b and 5b). We
also found a strong positive correlation among patients
with severe COPD between IL-6 and Sirt1 mRNA expres-
sion in current smokers and in patients without ICS treat-
ment (Figs. 4c and 5c). It is possible that the differences in
smoking status and inhaled steroid therapy affect the up-
ward shift of Sirt1 expression through IL-6 expression in
patients with severe COPD, because of the relatively lower
expression of IL-6 mRNA in ex-smokers and ICS treated
patients with severe COPD (Figs. 4a and 5a). However,
there is the possibility that the systemic inflammation and
serum inflammatory cytokine levels due to the disease
severity of COPD affected the expression of Sirt1 and its
related genes in blood cells. Further studies are needed to
characterize the effects of disease severity and inflam-
matory cytokines on Sirt1 expression in blood cells from
patients with COPD.
Although there was a significant correlation between
CD31 and Sirt1 mRNA expression, no significant correl-
ation was observed between the expression of CD34 and
Sirt1 mRNA. It is not surprising that the expression of
CD34 and CD31 in blood cells vary from patient to
patient, as CD31 is expressed in EPCs as well as plate-
lets, and macrophages from blood cells [8]. The weak
correlation between CD31 and CD34 indicates that it is
difficult to evaluate EPC expression in blood cells from
COPD patients by measuring the expression of a single
EPC related gene in whole blood cells.
Conclusion
In summary, our data demonstrated that EPC-related
gene expression in blood cells from smokers was not as-
sociated with the severity of COPD, despite the fact that
the expression of these genes was significantly decreased
in patients with moderate COPD compared to that in
smoking controls. The correlation between CD31 and
Sirt1 mRNA expression in blood cells from smokers and
the results obtained with cultured CD34+ progenitor
cells and HPMVECs in the presence of CSE suggest the
possibility that the Sirt1-p53 pathway is involved in
CD31 expression of blood cells in smokers. However,
further studies are necessary to clarify the pathobiologi-
cal role of Sirt1-related genes in patients with COPD.
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